TAKAHASHI Miho
Faculty of Life and Medical Sciences Department of Medical Life Systems
Assistant Professor
Last Updated :2022/12/05

Researcher Profile and Settings

Research Areas

  • Life sciences / Clinical pharmacy

Research Experience

  • 同志社大学工学部環境システム学科特別研究員, 2007 - 2008
  • 国立国際医療センター研究所臨床薬理研究部流動研究員, 2003 - 2007

Education

  • Hoshi University, 薬学研究科, 薬学専攻, 2003/04 - 2006/03
  • Hoshi University, Graduate School, Division of Pharmaceutical Sciences, - 2006
  • Hoshi University, 薬学研究科, 薬学専攻, 2001/04 - 2003/03
  • Hoshi University, Graduate School, Division of Pharmaceutical Sciences, - 2003
  • Hoshi University, Hoshi University, Hoshi University, - 2001
  • Hoshi University, Faculty of Pharmaceutical Science, - 2001

Awards

  • 腸管出血性大腸菌感染症研究会 奨励賞
    2012

Published Papers

  • Development of a novel tetravalent peptide that absorbs subtilase cytotoxin by targeting the receptor-binding B-subunit
    Shinichiro Hama; Miki Nakahara; Miho Watanabe-Takahashi; Eiko Shimizu; Hiroyasu Tsutsuki; Kinnosuke Yahiro; Kiyotaka Nishikawa
    Biochemical and Biophysical Research Communications, Elsevier BV, Sep. 2022, Scientific journal
  • A unique peptide-based pharmacophore identifies an inhibitory compound against the A-subunit of Shiga toxin
    Watanabe-Takahashi M; Senda M; Yoshino R; Hibino M; Hama S; Terada T; Shimizu K; Senda T; Nishikawa K
    Scientific Reports, Springer Science and Business Media LLC, 12:11443(1), Jul. 2022, Scientific journal
  • Identification of a peptide motif that potently inhibits two functionally distinct subunits of Shiga toxin
    Miho Watanabe-Takahashi; Masakazu Tamada; Miki Senda; Masahiro Hibino; Eiko Shimizu; Akiko Okuta; Atsuo Miyazawa; Toshiya Senda; Kiyotaka Nishikawa
    Communications Biology, Springer Science and Business Media LLC, 4(1), Dec. 2021, Scientific journal
  • A nontoxigenic form of Shiga toxin 2 suppresses the production of amyloid β by altering the intracellular transport of amyloid precursor protein through its receptor-binding B-subunit
    Waka Sato; Miho Watanabe-Takahashi; Takashi Hamabata; Koichi Furukawa; Satoru Funamoto; Kiyotaka Nishikawa
    Biochemical and Biophysical Research Communications, Elsevier BV, 557 247 - 253, Jun. 2021, Scientific journal
  • The Inducible Amphisome Isolates Viral Hemagglutinin and Defends Against Influenza A Virus Infection.
    Omi J; Watanabe-Takahashi M; Igai K; Shimizu E; Ching-Yi Tseng; Miyasaka, T; Waku T; Hama S; Nakanishi R; Goto Y; Nishino Y; Miyazawa A; Natori Y; Yamashita M; Kiyotaka Nishikawa K
    Nat. Commun., 11(1)162(1) doi; 10.1038/s41467-019-13974- - 162, Jan. 2020, Scientific journal
  • Synthetic construction of sugar-amino acid hybrid polymers involving globotriaose or lactose and evaluation of their biological activities against Shiga toxins produced by Escherichia coli O157:H7
    Koji Matsuoka; Kiyotaka Nishikawa; Yusuke Goshu; Tetsuo Koyama; Ken Hatano; Takahiko Matsushita; Miho Watanabe-Takahashi; Yasuhiro Natori; Daiyo Terunuma
    Bioorganic & Medicinal Chemistry, Elsevier BV, 26(22) 5792 - 5803, Dec. 2018, Scientific journal
  • Exosome-associated Shiga toxin 2 is released from cells and causes severe toxicity in mice.
    Miho Watanabe-Takahashi; Shinji Yamasaki; Masayuki Murata; Fumi Kano; Jun Motoyama; Jyoji Yamate; Jumpei Omi; Waka Sato; Hirofumi Ukai; Kentaro Shimasaki; Masaya Ikegawa; Miwa Tamura-Nakano; Ryohei Yanoshita; Yuri Nishino; Atsuo Miyazawa; Yasuhiro Natori; Noriko Toyama-Sorimachi; Kiyotaka Nishikawa
    Scientific reports, 8(1) 10776 - 10776, 17 Jul. 2018, Scientific journal
  • Acuired Resistance to Shiga toxin-induced apoptosis by loss of CD77 expression in Human myelogenous leukemia cell line, THP-1.
    Takahashi M; Hattori T; Watanabe-Takahashi M; Nishikawa K; Nito M
    Biological and Pharmaceutical Bulletin, 41;9 1475 - 1479, 2018
  • The pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy.
    Shimasaki K; Watanabe-Takahashi M; Umeda M; Funamoto S; Saito Y; Noguchi N; Kumagai K; hanada K; Tsukahara F; Maru Y; Shibata N; Naito M; Nishikawa K
    Genes to Cells, 2017
  • Affinity-Based Screening of Tetravalent Peptides Identifies SubtypeS-elective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition
    Takaaki Mitsui; Miho Watanabe-Takahashi; Eiko Shimizu; Baihao Zhang; Satoru Funamoto; Shinji Yamasaki; Kiyotaka Nishikawa
    INFECTION AND IMMUNITY, AMER SOC MICROBIOLOGY, 84(9) 2653 - 2661, Sep. 2016, Scientific journal
  • M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin
    Takayuki Hattori; Miho Watanabe-Takahashi; Isamu Shiina; Yoshimi Ohashi; Shingo Dan; Kiyotaka Nishikawa; Takao Yamori; Mikihiko Naito
    GENES TO CELLS, WILEY, 21(8) 901 - 906, Aug. 2016, Scientific journal
  • Development of a Novel Tetravalent Synthetic Peptide That Binds to Phosphatidic Acid
    Rina Ogawa; Kohjiro Nagao; Kentaro Taniuchi; Masaki Tsuchiya; Utako Kato; Yuji Hara; Takehiko Inaba; Toshihide Kobayashi; Yoshihiro Sasaki; Kazunari Akiyoshi; Miho Watanabe-Takahashi; Kiyotaka Nishikawa; Masato Umeda
    PLOS ONE, PUBLIC LIBRARY SCIENCE, 10(7), Jul. 2015, Scientific journal
  • Identification of a Wide Range of Motifs Inhibitory to Shiga Toxin by Affinity-Driven Screening of Customized Divalent Peptides Synthesized on a Membrane
    Mihoko Kato; Miho Watanabe-Takahashi; Eiko Shimizu; Kiyotaka Nishikawa
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMER SOC MICROBIOLOGY, 81(3) 1092 - 1100, Feb. 2015, Scientific journal
  • Proteasome inhibitors prevent cell death and prolong survival of mice challenged by Shiga toxin
    Takayuki Hattori; Miho Watanabe-Takahashi; Nobumichi Ohoka; Takashi Hamabata; Koichi Furukawa; Kiyotaka Nishikawa; Mikihiko Naito
    FEBS OPEN BIO, ELSEVIER SCIENCE LONDON, 5 605 - 614, 2015, Scientific journal
  • Identification of a Peptide-Based Neutralizer That Potently Inhibits Both Shiga Toxins 1 and 2 by Targeting Specific Receptor-Binding Regions
    Kazue Tsutsuki; Miho Watanabe-Takahashi; Yasuaki Takenaka; Eiji Kita; Kiyotaka Nishikawa
    INFECTION AND IMMUNITY, AMER SOC MICROBIOLOGY, 81(6) 2133 - 2138, Jun. 2013, Scientific journal
  • Substrate ectodomain is critical for substrate preference and inhibition of γ-secretase
    Satoru Funamoto; Toru Sasaki; Seiko Ishihara; Mika Nobuhara; Masaki Nakano; Miho Watanabe-Takahashi; Takashi Saito; Nobuto Kakuda; Tomohiro Miyasaka; Kiyotaka Nishikawa; Takaomi C. Saido; Yasuo Ihara
    Nature Communications, 4, 2013, Scientific journal
  • An Orally Applicable Shiga Toxin Neutralizer Functions in the Intestine To Inhibit the Intracellular Transport of the Toxin
    Miho Watanabe-Takahashi; Toshio Sato; Taeko Dohi; Noriko Noguchi; Fumi Kano; Masayuki Murata; Takashi Hamabata; Yasuhiro Natori; Kiyotaka Nishikawa
    INFECTION AND IMMUNITY, AMER SOC MICROBIOLOGY, 78(1) 177 - 183, Jan. 2010, Scientific journal
  • Yip1A regulates the COPI-independent retrograde transport from the Golgi complex to the ER
    Fumi Kano; Shinobu Yamauchi; Yumi Yoshida; Miho Watanabe-Takahashi; Kiyotaka Nishikawa; Nobuhiro Nakamura; Masayuki Murata
    JOURNAL OF CELL SCIENCE, COMPANY OF BIOLOGISTS LTD, 122(13) 2218 - 2227, Jul. 2009, Scientific journal
  • Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis
    Norihito Shibata; Kou-ichi Jishage; Makoto Arita; Miho Watanabe; Yosuke Kawase; Kiyotaka Nishikawa; Yasuhiro Natori; Hiroyasu Inoue; Hitoshi Shimano; Nobuhiro Yamada; Masafumi Tsujimoto; Hiroyuki Arai
    FASEB JOURNAL, FEDERATION AMER SOC EXP BIOL, 20(14) 2642 - +, Dec. 2006, Scientific journal
  • A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin
    Kiyotaka Nishikawa; Miho Watanabe; Eiji Kita; Katsura Igai; Kazumi Omata; Michael B. Yaffe; Yasuhiro Natori
    FASEB JOURNAL, FEDERATION AMER SOC EXP BIOL, 20(14) 2597 - +, Dec. 2006, Scientific journal
  • Development of dialyzer with immobilized glycoconjugate polymers for removal of Shiga-toxin
    A Miyagawa; M Watanabe; K Igai; MCZ Kasuya; Y Natori; K Nishikawa; K Hatanaka
    BIOMATERIALS, ELSEVIER SCI LTD, 27(17) 3304 - 3311, Jun. 2006, Scientific journal
  • Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues
    M Watanabe; K Igai; K Matsuoka; A Miyagawa; T Watanabe; R Yanoshita; Y Samejima; D Terunuma; Y Natori; K Nishikawa
    INFECTION AND IMMUNITY, AMER SOC MICROBIOLOGY, 74(3) 1984 - 1988, Mar. 2006, Scientific journal
  • Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation
    K Nishikawa; K Matsuoka; M Watanabe; K Igai; K Hino; K Hatano; A Yamada; N Abe; D Terunuma; H Kuzuhara; Y Natori
    JOURNAL OF INFECTIOUS DISEASES, UNIV CHICAGO PRESS, 191(12) 2097 - 2105, Jun. 2005, Scientific journal
  • Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections
    M Watanabe; K Matsuoka; E Kita; K Igai; N Higashi; A Miyagawa; T Watanabe; R Yanoshita; Y Samejima; D Terunuma; Y Natori; K Nishikawa
    JOURNAL OF INFECTIOUS DISEASES, UNIV CHICAGO PRESS, 189(3) 360 - 368, Feb. 2004, Scientific journal

MISC

  • Synthesis and biological evaluation of glycopolymer as Shiga toxin neutralizer
    K Matsuoka; A Miyagawa; K Nishikawa; M Watanabe; Y Natori; E Kita; T Koyama; K Hatano; D Terunuma
    GLYCOBIOLOGY, OXFORD UNIV PRESS INC, 14(11) 1194 - 1194, Nov. 2004, Summary international conference

Presentations

  • P210 BCR-ABLのPHドメインを標的とした新規ペプチド性CML治療薬の開発
    長田 雅也; 高橋 美帆; 島﨑 健太朗; 柴田 識人; 内藤 幹彦; 西川 喜代孝
    第41回日本分子生物学会, 2018
  • 受容体結合部位を標的とした新規ペプチド性Subtilase cytotoxin阻害薬の開発
    中原美樹; 高橋美帆; 及川英子; 八尋錦之助; 西川喜代孝
    第22回腸管出血性大腸菌感染症研究会, 2018
  • 酵素活性部位を標的とした新規ペプチド性Stx阻害薬の開発
    日比野雅大; 高橋美帆; 玉田真一; 千田美紀; 奥田明子; 宮澤淳夫; 千田俊哉; 西川喜代孝
    第22回腸管出血性大腸菌感染症研究会, 2018
  • 新規CaMK2阻害ペプチドによるA型インフルエンザウイルス感染制御法の確立
    濱 信一郎; 近江 純平; 中村 友美; 西村 浩輝; 高橋 美帆; 西川 喜代孝
    第91回日本生化学会, 2018
  • RANK-TRAF6 signalを標的とした破骨細胞分化制御ペプチドの開発
    安西 聖敬; 高橋 美帆; 中村友美; 川端 宏; 田口祐; 井上純一郎; 西川喜代孝
    第91回日本生化学会, 2018
  • Exosome-associated Shiga toxin 2 is released from cells and causes severe toxicity in mice.
    Miho Watanabe-Takahashi; Shinji Yamasaki; Masayuki Murata; Fumi Kano; Jun Motoyama; Jyoji Yamate; Jumpei Omi; Waka Sato; Hirofumi Ukai; Kentaro Shimasaki; Masaya Ikegawa; Miwa Tamura-Nakano; Ryohei Yanoshita; Yuri Nishino; Atsuo Miyazawa; Yasuhiro Natori; Noriko Toyama-Sorimachi; Kiyotaka Nishikawa
    VTEC2018, 2018
  • Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues
    VTEC2006, 2006, Poster presentation
  • Carbohydorate-containing linear polymers that neutralize Shiga toxin
    VTEC 2003, 2003, Poster presentation

Industrial Property Rights

  • Patent right
    P210 PH結合ペプチドおよび慢性骨髄性白血病治療薬
    西川喜代孝, 高橋美帆, 島崎健太朗, 長田雅也
    特願2018-210822
  • Patent right
    Stx1毒性阻害ペプチドおよびStx1に起因する疾患の治療薬
    西川喜代孝, 高橋美帆, 津々木一恵
    特願2010-019315, 特願2010-019315
  • Patent right
    Stx2阻害4価ペプチドおよびこのStx2阻害4価ペプチドを含む治療薬
    西川喜代孝, 高橋美帆, 三井貴瑛, 山崎伸二
    特願2013-13746, 特願2013-13746
  • Patent right
    LT阻害4価ペプチドおよびETEC感染症治療薬
    西川喜代孝, 高橋美帆, 谷川哲也
    特願2014-128632, 特願2014-128632
  • Patent right
    CT阻害4価ペプチドおよびコレラ治療薬
    西川喜代孝, 高橋美帆, 山本洋, 濱端崇
    特願2013-51032, 特願2014-050828
  • Patent right
    CaMKII阻害ペプチドおよびこれを含有するCaMKII阻害剤
    西川喜代孝, 高橋美帆, 西村浩輝, 高柳広, 尾藤晴彦
    特許第5754008号, 特許第5754008号
  • Patent right
    ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
    西川喜代孝, 高橋美帆, 近江純平
    特願2016-164971, 特願2016-164971
  • Patent right
    Stx毒性阻害ペプチドおよびStxに起因する疾患の治療薬
    西川喜代孝, 高橋美帆, 津々木一恵
    特許第5635779号, 特許第5635779号
  • Patent right
    破骨細胞分化制御ペプチド、および、破骨細胞分化に関連する疾患の含有する治療薬
    西川喜代孝, 高橋美帆, 安西聖敬, 川端宏, 水野沙緒利
    特願2018-163521, 特願2018-163521
  • Patent right
    抗インフルエンザウイルス活性ペプチドおよびインフルエンザウイルス感染症の予防・治療薬
    西川喜代孝, 高橋美帆, 近江純平, 濱信一郎
    特願2018-163326, 特願2018-163326

Research Seeds

  • Development of a novel therapeutic agent for CML that targets a PH domain of p210-BCR-ABL
    Research Fields: Medical and Pharmaceutical Sciences
    Summary: The tyrosine kinase inhibitors (TKIs) for CML treatment causes drug-resistance, and shows only a poor effect against CML stem cells. In CML cells and CML stem cells, it has been shown that a high level of ROS production is sustained to promote the proliferation of these cells. Thus, the compound targeting the PH domain to regulate its function can be a novel type of therapeutic agent against CML.
  • A new technology identifying a specific peptide-based inhibitor for a protein kinase.
    Research Fields: Medical and Pharmaceutical Sciences, Life Sciences
    Affiliation/Name: Kiyotaka Nishikawa:Miho Takahashi

    Patent Information: 特願2014-128632, 特願2010-019731, 特願2010-019728